Two Eli Lilly manufacturing crops in Indiana are getting a $5.3 billion increase to extend manufacturing of Zepbound and Mounjaro, the corporate stated Might 24. 

The funding “represents the only largest funding in artificial medication [active pharmaceutical ingredient] manufacturing in U.S. historical past,” Eli Lilly’s chair and CEO David Ricks stated in a information launch. 

Leaders of the manufacturing websites in Lebanon, Ind., will rent 200 full-time staff to assist improve manufacturing. Mounjaro is permitted for Sort 2 diabetes and Zepbound is indicated for continual weight administration. Eli Lilly can be eyeing a Zepbound label growth after discovering constructive ends in a sleep apnea trial. 

The announcement raises the corporate’s whole funding within the Lebanon web site from $3.7 billion to $9 billion.